Jubilant Ingrevia Share: Why Nuvama Believes It Can Be the Next Big Chemical Winner?

Synopsis: Jubilant Ingrevia Limited is in focus after Nuvama maintained a “Buy” rating with a target price of ₹994, implying 42% upside potential. The brokerage cited strong Q4 earnings, robust growth in the Nutrition and Specialty Chemicals segments, recovery in intermediates, and a strong product and CDMO pipeline as key growth drivers.

The shares of a Small-Cap company specialising in the manufacturing of specialty chemicals, nutrition and health solutions, and chemical intermediates for pharmaceutical, agrochemical, and industrial sectors are in focus following the buy target by Nuvama.

With a market capitalization of Rs. 10,365 crores in the day’s trade, the shares of Jubilant Ingrevia Ltd closed at Rs. 650.75 down 4 percent from its previous day’s close price of Rs. 679.40.

What Happened 

Jubilant Ingrevia Limited, engaged in specialty chemicals, nutrition, and chemical intermediates manufacturing, is in focus after Nuvama maintained a “Buy” rating on the stock with a target price of Rs. 994, implying an upside potential of 42 percent from the previous day’s close.

Strong Q4 Earnings Beat

Jubilant Ingrevia delivered a better-than-expected Q4 performance, with EBITDA and PAT surpassing estimates by around 8% and 16%, respectively. Strong operational execution, improving product mix, and healthy demand trends boosted profitability, strengthening investor confidence and supporting Nuvama’s positive outlook on future earnings growth.

Nutrition Segment Driving Growth

The Nutrition business emerged as the key growth driver during the quarter, supported by strong demand, improved realizations, and better margins. Recovery in this segment indicates improving market conditions and operational stability, which could contribute meaningfully to overall profitability and provide sustained earnings support over the coming quarters.

Healthy Specialty Chemicals Momentum

The Specialty Chemicals business continues to maintain healthy growth momentum despite concerns around innovator-linked exposure. Stable demand, diversified applications, and expanding customer relationships are supporting revenue visibility. Nuvama believes the segment’s long-term potential remains intact, helping offset temporary uncertainties linked to large customer contracts and industry cycles.

Recovery in the Intermediates Segment

The Intermediates segment is witnessing a gradual recovery after a challenging phase marked by weak demand and pricing pressure. Improving utilization levels, stabilizing input costs, and better industry conditions are supporting margin improvement. Continued recovery in this business can enhance operating leverage and strengthen overall earnings momentum for the company.

Robust Product & CDMO Pipeline

Jubilant Ingrevia’s strong pipeline across specialty chemicals, nutrition products, and CDMO opportunities provides long-term growth visibility. New product launches, capacity expansion, and customer additions are expected to support revenue growth. The company’s diversified business structure also improves resilience against cyclical fluctuations across individual segments and end markets.

Cautious Watch on Innovator Exposure

While maintaining a Buy rating, Nuvama remains cautiously watchful of the large innovator-linked CDMO contract due to execution and dependency risks. Any delay or moderation in innovator demand could impact near-term growth. However, the brokerage believes the company’s diversified operations and improving core businesses provide sufficient support to sustain growth momentum.

Financials & Others

Its revenue from operations increased by 12.2 percent YoY from Rs. 1,051 Crores in Q4FY25 to Rs. 1,179 Crores in Q4FY26, and it also rose by 12.2 percent QoQ from Rs. 1,051Crores in Q3FY26 to Rs. 1,179 Crores in Q4FY26.

Its Net Profit increased by 16.2 percent YoY from Rs. 74 Crores in Q4FY25 to Rs. 86 Crores in Q4FY26, and it also rose by 83 percent QoQ from Rs. 47 Crores in Q3FY26 to Rs. 86 Crores in Q4FY26.

Jubilant Ingrevia Limited reported a ROCE of 11.4% and ROE of 9.51%, while maintaining a low debt-to-equity ratio of 0.25, indicating a relatively stable financial position and controlled leverage.

The company has also maintained a healthy dividend payout ratio of 29.6%. Additionally, its working capital requirements improved significantly, reducing from 29.4 days to 22 days, reflecting better operational efficiency and cash flow management.

Jubilant Ingrevia Limited is a leading Indian specialty chemicals company engaged in the manufacturing of specialty chemicals, nutrition and health solutions, and chemical intermediates. The company serves diverse industries, including pharmaceuticals, agrochemicals, consumer products, nutrition, and industrial applications across domestic and global markets.

The company has a strong global presence with operations across India, Europe, North America, and other international markets. Jubilant Ingrevia is known for its diversified product portfolio, integrated manufacturing capabilities, strong R&D focus, and long-term customer relationships, helping it maintain steady growth and operational efficiency.

Jubilant Ingrevia Limited has a well-diversified application portfolio in FY26, with Pharma contributing 34% of revenue, followed by Industrial at 23%, while Agro and Nutrition contributed 19% each, and the consumer applications accounted for the remaining 4%.

The company’s business mix is led by Specialty Chemicals, which contributed 44% of revenue, followed by Chemical Intermediates at 38% and Nutrition & Health Solutions at 18%. Specialty Chemicals and Nutrition together contributed over 62% of total revenue.

Geographically, India remained the largest market with a 56% revenue contribution, while Europe accounted for 24%. North America accounts 8%, and the rest of the World in 12%, highlighting strong international growth momentum.

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.

The post Jubilant Ingrevia Share: Why Nuvama Believes It Can Be the Next Big Chemical Winner? appeared first on Trade Brains.